Wagner J*, Gößl D*, Ustyanovska N, Xiong M, Hauser D, Zhuzhgova O, Hocevar S, Taskoparan B, Poller L, Datz S, Engelke H, Daali Y, Bein T*, Bourquin C*. (*shared first and senior authorship)
Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice. ACS Nano, 2021, 15:4450–4466. (JIF 14.6)
2020
Hérault N*, Wagner J*, Abram SL, Widmer J, Horvath L, Vanhecke D, Bourquin C*,. Fromm M*. (*shared first and senior authorship)
Silver-containing titanium oxide nanocapsules for combating multidrug-resistant bacteria International Journal of Nanomedicine, 2020, 15:1267-1281 (JIF 4.5)
2019
Hočevar S, Milošević A, Rodriguez-Lorenzo L, Ackermann-Hirschi L, Mottas I, Petri-Fink A, Rothen-Rutishauser B, Bourquin C*, Clift MJD* (*shared senior authorship)
Polymer-coated gold nanospheres do not impair the innate immune function of human B lymphocytes in vitro ACS Nano, 2019, 13:6790-6800. (JIF 13.9)
Thauvin C, Widmer J, Mottas I, Hocevar S, Allémann E, Bourquin C*, Delie F* (*shared senior authorship)
Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study Eur J Pharm Biopharm, 2019, 139:253-261. (JIF 4.6)
Rapp M, Wintergerst M, Kunz W, Vetter V, Knott M, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C*, von Andrian U*, Endres S*, Anz D* (*shared senior authorship)
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes Journal of Experimental Medicine, 2019, 216:1170-1181. (JIF 10.8)
Mottas I*; Bekdemir A*; Cereghetti A; Spagnuolo L; Yang YS; Müller M; Irvine D; Stellacci F*; Bourquin C* (*shared first and senior authorship)
Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation Biomaterials, 2019, 190-191:111-120. (JIF 8.8)
Bourquin C., Pommier A., Hotz C.
Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists Pharmacological Research 2019, 154:104192 (Review)
Bourquin C.
Bionanomaterials for the Delivery of Cancer Immunotherapy Chimia 2019, 73:69-72 (Review)
2018
Lucke M, Mottas I, Herbst T, Hotz C, Römer L, Schierling M, Slotta U, Spinetti T, Scheibel T*, Winter G*, Bourquin C*, Engert J* (*shared senior authorship)
Engineered hybrid spider silk particles as delivery system for peptide vaccines Biomaterials, 2018, 172:105-115. (JIF 8.4)
Widmer J, Thauvin C, Mottas I, Nguyen V, Delie F, Allémann E, Bourquin C.
Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation International Journal of Pharmaceutics, 2018, 535:444-451. (JIF 3.7)
Spöring I, Martinez VA., Hotz C, Schwartz-Linek J, Grady KL, Nava-Sedeño JM, Vissers T, Singer HM, Rohde M, Bourquin C, Hatzikirou H, Poon WCK, Dufour YS, Erhardt M
Hook length of the bacterial flagellum is optimized for maximal stability of the flagellar bundle Plos Biology, 2018, 16(9):e2006989 (JIF 9.1)
2017
Secondini C, Coquoz O, Spagnuolo L, Spinetti T, Peyvandi S, Ciarloni L, Botta F, Bourquin C, Rüegg C
Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade Oncoimmunology, 2017, 6:e1316437. (JIF 7.6)
Oberson A*, Spagnuolo L*, Puddinu V, Barchet W, Rittner K, Bourquin C. (*shared first authorship)
NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I IFN response Oncotarget, 2017, 9:5641-5651. (JIF 5.1)
Mottas I, Milosevic A, Petri-Fink A, Rothen-Rutishauser B, Bourquin C
A rapid screening method to evaluate the impact of nanoparticles on macrophages Nanoscale, 2017, 9:2492-2504. (JIF 7.8)
Priebe M*, Widmer J*, Suhartha Löwa N, Abram SL, Mottas I, Woischnig AK, Brunetto PS, Khanna N, Bourquin C*, Fromm K*. (*shared first and senior authorship)
Antimicrobial silver-filled silica nanorattles with low immunotoxicity in dendritic cells Nanomedicine, 2017, 13:11-22. (JIF 5.7)
2016
Hotz C*, Treinies M*, Mottas I, Rötzer LC, Oberson A, Spagnuolo L, Perdicchio M, Spinetti T, Herbst T, Bourquin C. (*shared first authorship)
Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses Oncoimmunology, 2016, 5:e1232219. (JIF 7.6)
Spinetti T, Spagnuolo L, Mottas I, Secondini C, Treinies M, Rüegg C, Hotz C, Bourquin C.
TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function Oncoimmunology, 2016, 5:e1230578. (JIF 7.6)
Heidegger S, Gößl D, Schmidt A, Niedermayer S, Argyo C, Endres S, Bein T, Bourquin C.
Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery Nanoscale, 2016, 8:938-48. (JIF 7.8)
Piccand M, Bessa J, Schick E, Senn C, Bourquin C, Richter WF
Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice Journal of the American Association of Pharmaceutical Scientists, 2016, 18:354-61 (JIF 3.8)
2015
Anz D, Rapp M, Eiber S, Koelzer VH, Thaler R, Haubner S, Knott M, Nagel S, Golic M, Wiedemann GM, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S, Bourquin C.
Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression Cancer Research, 2015, 75:4483-93. (JIF 9.3)
Hotz C, Roetzer LC, Huber T, Sailer A, Oberson A, Treinies M, Heidegger S, Herbst T, Endres S, Bourquin C.
TLR and RLR Signaling Are Reprogrammed in Opposite Directions after Detection of Viral Infection Journal of Immunology, 2015, 195:4387-95. (JIF 5.4)
Heidegger S, Jarosch A, Schmickl M, Endres S, Bourquin C, Hotz C
Mycoplasma hyorhinis-Contaminated Cell Lines Activate Primary Innate Immune Cells via a Protease-Sensitive Factor PLoS One., 2015;10:e0142523. (JIF 3.2)
Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger J, Schnurr M, Rothenfusser S, Schendel D, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.
Selective bispecific T-cell recruiting antibody and anti-tumor activity of adoptive T-cell transfer. Journal of the National Cancer Institute, 2014, 107:364. Print Jan 2015 (JIF 15.2)
2014
Roehnisch T, Then C, Nagel W, Blumenthal C, Braciak T, Donzeau M, Böhm T, Flaig M, Bourquin C*, Oduncu F* (*shared senior authorship)
Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma. Journal of Translational Medicine 2014, 12:119 (JIF 3.5)
Anz D, Kruger S, Haubner S, Rapp M, Bourquin C, Endres S.
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Diabetes Obesity and Metabolism 2014, 16 :569-72 (JIF 5.2)
2013
Heidegger S, Anz D, Stephan N, Bohn B, Herbst T, Fendler WP, Suhartha N, Sandholzer N, Kobold S, Hotz C, Eisenächer K, Radtke-Schuller S, Endres S, Bourquin C.
Virus-associated activation of innate immunity induces rapid disruption of Peyer's patches in mice. Blood 2013, 122:2591-9. (JIF 9.0)
Röhnisch T, Then C, Nagel W, Blumenthal C, Braciak T, Donzeau M, Böhm T, Bourquin C*, Oduncu F* (*shared senior authorship)
Chemically linked Phage Idiotype Vaccination in the murine B Cell Lymphoma 1 Model Journal of Translational Medicine 2013, 11:267 (JIF 3.5)
Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, Guarda G, Tian Z, Tschopp J, Zhou R.
Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013, 38:1154-63. (JIF 19.8)
Heidegger S, Kirchner S, Stephan N, Bohn B, Suhartha N, Hotz C, Anz D, Sandholzer N, Stecher B, Rüssmann H, Endres S, Bourquin C.
TLR activation excludes circulating naive CD8+ T cells from gut-associated lymphoid organs in mice. Journal of Immunology 2013, 190:5313-20 (JIF 5.6)
2012
Przewoznik M, Hömberg N, Naujoks M, Pötzl J, Münchmeier N, Brenner CD, Anz D, Bourquin C, Nelson PJ, Röcken M, Mocikat R.
Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer. Journal of Immunotherapy 2012, 35:217-22. (JIF 3.2)
Vollbrecht T, Stirner R, Tufman A, Roider J, Huber RM, Bogner JR, Lechner A, Bourquin C, Draenert R.
Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS 2012, 26(12):F31-7 (JIF 6.3)
Herbst T, Esser J, Prati M, Kulagin M, Stettler R, Zaiss MM, Hewitson JP, Merky P, Verbeek JS, Bourquin C, Camberis M, Prout M, Maizels RM, Le Gros G, Harris NL.
Antibodies and IL-3 support helminth-induced basophil expansion. PNAS 2012, 109 (37) (JIF 9.6)
Hotz C, Bourquin C.
Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything Authors’ view Oncoimmunology, 1:227-228 (Review)
2011
Anz D, Eiber S, Scholz C, Endres S, Kirchner T, Bourquin C, Mayr D.
In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype. Histopathology 2011, 59:965-74 (JIF 3.6)
Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, Storch B, Sandholzer N, Wurzenberger C, Anz D, Endres S (2011).
Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Research, 71:5123-33 (JIF 7.5) Authors’ View in: Oncoimmunology 2011, 1: 227-228
Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzer P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, Anz D, Bourquin C, Maraskovsky E, Endres S, Schnurr M.
ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross- priming of CD8+ T cells. Journal of Immunology 2011, 187:55-63 (JIF 5.6)
Loschko J, Schlitzer A, Dudziak D, Drexler I, Sandholzer N, Bourquin C, Reindl W, Krug AB.
Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity. Journal of Immunology 2011, , 186:6718-25 (JIF 5.6)
Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C.
CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clinical Cancer Research 2011 -- Comment in: Clinical Cancer Research 2011, 17:1765-75 (2012), 17:1765-75 (JIF 6,7)
2010
Anz D, Mueller W, Golic M, Koelzer V, Ellermeier J, Schnurr M, Bourquin C*, Endres S. (* corresponding author)
CD103 is a hallmark of tumor-infiltrating regulatory T cells. International Journal of Cancer 2010, 184:939-46 (JIF 4,7)
Bourquin C, Wurzenberger C, Fuchs S, Anz D, Weigel S, Sandholzer N, Winter G, Coester C, Endres S.
Delivery of immunostimulatory RNA oligonucleotides by gelation nanoparticles triggers an efficient antitumoral response. Journal of Immunotherapy 2010, 33:935-44 (JIF 3,2)
Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, Wurzenberger C, Denzel A, Kammerer R, Zimmermann W, Endres S.
Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in a SV40 T antigen mouse model. Journal of Immunology 2010, 185:2580-8 (JIF 5,6)
Anz D, Koelzer VH, Moder S, Thaler R, Schwerdt T, Lahl K, Sparwasser T, Besch R, Poeck H, Hornung V, Rothenfusser S, Bourquin C*, Endres S. (* corresponding author)
Blockade of regulatory T cell suppression by Toll-like receptor 7-activating immunostimulatory RNA oligonucleotides. Journal of Immunology 2010, 184:939-46 (JIF 6,1)
2009
Berchtold C, Panthel K, Jellbauer S, Köhn B, Roider E, Partilla M, Heesemann J, Endres S, Bourquin C, Rüssmann H.
Superior Protective Immunity against Murine Listeriosis by Combined Vaccination with CpG DNA and Recombinant Salmonella. Infection and Immunity 2009, 77:5501-08 (JIF 4,0)
Bourquin C, Schmidt L, Lanz AL, Storch B, Wurzenberger C, Anz D, Berger M, Poeck H, Hartmann G, Hornung V, Endres S.
Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK-cell response through the Toll-like receptor 7. Journal of Immunology 2009, 183:6078-86 (JIF 6,1)
Ablasser A, Poeck H, Anz D, Berger M, Schlee M, Kim S, Bourquin C, Rothenfusser S, Endres S, Hartmann G, Hornung V.
Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. Journal of Immunology 2009, 182:6824-33 (JIF 6,1)
Anz D, Thaler R, Stephan N, Waibler Z, Trauscheid JM, Scholz C, Kalinke U, Barchet W, Endres S, Bourquin C.
Activation of melanoma differentiation-associated gene 5 (MDA-5) causes rapid involution of the thymus. Journal of Immunology 2009, 182:6044-50 (JIF 6,1)
Wurzenberger C, Koelzer VH, Schreiber S, Anz D, Vollmar AM, Schnurr M, Endres S, Bourquin C.
Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo. Cancer Immunology Immunotherapy 2009, 58:901-13 (JIF 3,7)
Haasters F, Prall W, Anz D, Bourquin C, Endres S, Mutschler W, Docheva D and Schieker M.
Morphological and immunological characteristics indicate the yield of early progenitors and represent a quality control for human mesenchymal stem cell culturing. Journal of Anatomy 2009, 214:759-767 (JIF 2,0)
2008
Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya S, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Häcker G, Neuenhahn M, Busch D, Rothenfusser S, Prinz M, Hornung V, Endres S, Tüting T, Hartmann G.
5´-triphosphate-siRNA: turning gene silencing and RIG-I activation against melanoma. Nature Medicine 2008, 14:1256-63. (JIF 26,4)
Bourquin C, Anz D, Zwiorek K, Lanz AL, Fuchs S, Weigel S, Wurzenberger C, von der Borch P, Golic M, Moder S, Winter G, Coester C, Endres S.
Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. Journal of Immunology 2008, 181:2990-8. (JIF 6,1)
Bourquin C, van der Haar M, Anz D, Sandholzer N, Neumaier I, Endres S, Skerra A, Schwab ME, Linington C.
DNA vaccination efficiently induces antibodies to Nogo-A and does not exacerbate experimental autoimmune encephalomyelitis. European Journal of Pharmacology 2008, 588:99-105. (JIF 2,4)
Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, Coester C.
Delivery by Cationic Gelatin Nanoparticles Strongly Increases the Immunostimulatory Effects of CpG Oligonucleotides. Pharmaceutical Research 2008, 25:551-62. (JIF 2,7)
Bourquin C, Anz D, Rothenfußer S, Endres S.
Toll-like-Rezeptoren als neue Marker und Targets der Pharmakotherapie Symposium der Novartis Stiftung, Schattauer Verlag , (Review)
Endres S, Anz D, Bourquin C.
Biomarker: Anwendung in der Praxis – Beispiel Gastroenterologie Symposium der Novartis Stiftung, Schattauer Verlag , (Review)
2007
Bourquin C, Schmidt L, Hornung V, Wurzenberger C, Anz D, Sandholzer N, Schreiber S, Voelkl A, Hartmann G, Endres S.
Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T cell and IgG2a response. Blood 2007, 109:2953-2960. (JIF 10,9)
Bourquin C.
[Do obese patients need higher dosages? (interview by Dr. Neumaier)] MMW-Fortschritte der Medizin, 149:15. (Review)
2006
Bourquin C, Schreiber S, Beck S, Hartmann G, Endres S.
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. International Journal of Cancer 2006, 118:2790-2795. (JIF 4,4)
2005
Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G.
Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Medicine 2005, 11:263-70. (JIF 26,4)
2003
Bourquin C, Schubart A, Tobollik S, Mather I, Ogg S, Liblau R, Linington C.
Selective unresponsiveness to conformational B cell epitopes of the myelin oligodendrocyte glycoprotein in H-2b mice Journal of Immunology 2003, 171:455-61 (JIF 6,1)
Pagany M, Jagodic M, Bourquin C, Olsson T, Linington C.
Genetic variation in myelin oligodendrocyte glycoprotein expression and susceptibility to experimental autoimmune encephalomyelitis Journal of Neuroimmunology 2003, 139:1-8 (JIF 3,2)
2002
Abdul-Majid KB, Stefferl A, Bourquin C, Lassmann H, Linington C, Olsson T, Kleinau S, Harris RA.
Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scandinavian Journal of Immunology 2002, 50: 70-81 (JIF 1,7)
2000
Bourquin C, Iglesias A, Berger T, Wekerle H, Linington C.
Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalitis. European Journal of Immunology 2000, 30:3663-7 (JIF 5,4)
1999
Stefferl A, Brehm U, Storch M, Lambracht-Washington D, Bourquin C, Wonigeit K, Lassmann H, Linington C.
Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the „resistant“ brown norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response. Journal of Immunology 1999, 163:40-9 (JIF 6,1)